In this Review:
Epigenetic biomarkers predict UC-associated neoplasia
Reassuring data on infliximab biosimilar in IBD
Infliximab level-based dosing in IBD: very good outcomes
Long-term SC ustekinumab safe and efficacious in CD
Perioperative vedolizumab: no increased risk of infectious complications
Histological remission predicts clinical remission in UC
FMT induces remission in mild-tomoderate UC
HealthPROMISE app improves QOL outcomes in IBD
Benefits of the modified-Rutgeerts’ postoperative score
Faecal calprotectin correlates with histological disease activity
Please login below to download this issue (PDF)